Substituted tricyclics
OwnerHo-Shen Lin, Michael Enrico Richettinventors
Life of this patent
Estimating the term…
Abstract
A class of novel indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
Claims24
A compound of the formula (I)
- 104
- wherein;
- Z is phenyl,
- 4
- R20 is the group -(L)-R80;
- where, (L)- is a divalent linking group of 1 to 12 atoms selected from carbon, and
- hydrogen, where R80 is phenyl;
- R21 is a hydrogen or C1-C4 alkyl;
- R1 is —CONH2;
- R2′ is the group
- —O(CH2)tR5′ where
- R5′ is the group -(Lh)-(acylamino acid), wherein -(Lh)- is an acylamino acid linker having an acylamino acid linker length of 1 to 7 and t is 1-5;
- wherein the (acylamino acid) group is represented by
- 105
- wherein NR9a is hydrogen, (C1-C6) alkyl or (C1-C6) alkoxy;
- wherein NR9b is an amino acid residue;
- R3′ is selected from hydrogen, C1-C14 alkyl;
- or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, or salt, thereof.
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
A method of treating sepsis, septic shock, rheumatoid arthritis, osteoarthritis, stroke, apoptosis, asthma, chronic bronchitis, acute bronchitis, cystic fibrosis, inflammatory bowel disease, or pancreatitis which comprises administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula I
- 106
- wherein;
- Z is cyclohexenyl, or phenyl,
- R4 is selected from groups (a), (b) and (c) where;
- (a) is 13 (C5-C20)alkyl, —(C5-C20)alkenyl, —(C5-C20)alkynyl, carbocyclic radicals, or heterocyclic radicals, or
- (b) is a member of (a) substituted with one or more independently selected non-interfering substituents;
- or
- (c) is the group -(L)-R80;
- where, (L)—is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur;
- wherein the combination of atoms in -(L)- are selected from the group consisting of (i) carbon and hydrogen only, (ii) one sulfur only, (iii) one oxygen only, (iv) one or two nitrogen and hydrogen only, (v) carbon, hydrogen, and one sulfur only, and (vi) an carbon, hydrogen, and oxygen only;
- and where R80 is a group selected from (a) or (b);
- R21 is a non-interfering substituent where f is 1-3;
- R1 is —NHNH2, —NH2, or —CONH2;
- R2′ is the group —O(CH2)tR5′ where
- R5′ is (a) —CONR9R10 where R9 and R10 are independently Hydrogen, —(C1-C6)alkyl or —CF3;
- phenyl or phenyl substituted with —(C1-C6)alkyl;
- or
- (b) -(Lh)-(acylamino acid) group, wherein -(Lh)- is an acylamino acid linker having an “acylamino acid” linker length of 1 to 7 and t is 1-5;
- R3′ is selected from non-interfering substituent, carbocyclic radicals, carbocyclic radicals substituted with non-interfering substituents, heterocyclic radicals, and heterocyclic radicals substituted with non-interfering substituents;
- or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.
(Cancelled)
(Cancelled)
(Cancelled)
(Cancelled)
A compound which is selected from the group consisting of;
- 107
- 108
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine
- 109
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine methyl ester
- 110
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine
- 111
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine
- 112
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine methyl ester
- 113
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine
- 114
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine
- 115
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine methyl ester
- 116
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine
- 117
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid
- 118
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid dimethyl ester
- 119
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid
- 120
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid
- 121
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid dimethyl ester
- 122
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid
- 123
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine
- 124
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine methyl ester
- 125
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine
- 126
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine
- 127
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine methyl ester
- 128
- and
- N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine
- 129
- or a pharmaceuticallt acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt thereof.
(Cancelled)
Dependencies are inferred from the claim text.